IMMUNOGLOBULIN A NEPHROPATHY
Clinical trials for IMMUNOGLOBULIN A NEPHROPATHY explained in plain language.
Never miss a new study
Get alerted when new IMMUNOGLOBULIN A NEPHROPATHY trials appear
Sign up with your email to follow new studies for IMMUNOGLOBULIN A NEPHROPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for kids with rare kidney diseases: drug trial targets protein leak
Disease control Recruiting nowThis study tests a drug called sparsentan in 67 children with certain kidney diseases that cause protein to leak into urine. The goal is to see if the drug is safe and can reduce protein levels over 108 weeks. Participants take the drug once daily as a liquid or tablet.
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY
Phase: PHASE2 • Sponsor: Travere Therapeutics, Inc. • Aim: Disease control
Last updated Apr 29, 2026 06:57 UTC
-
New hope for kidney disease: drug trial targets protein leak to preserve function
Disease control Recruiting nowThis study tests whether the drug ravulizumab can reduce protein in the urine and protect kidney function in adults with IgA nephropathy, a disease that can lead to kidney failure. About 510 participants will receive either ravulizumab or a placebo by infusion. The main goals are…
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY
Phase: PHASE3 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Apr 29, 2026 06:56 UTC